- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01485523
Sensitivity and Specificity of Nasal Provocation Test in Allergic Rhinitis to House Dust Mites
Panoramica dello studio
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
-
Strasbourg, Francia, 67000
- Pole de pathologie thoracique.Unité d'allergologie, d'asthmologie et de pathologie respiratoire de l'environnement
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Non-smoking or smoking less than five cigarettes per day
- Subject affiliated with a social security system
- Informed consent signed and dated by the investigator and the subject
- Having been informed about the results of prior medical
Exclusion Criteria:
- Moderate to severe persistent asthma (FEV <70%)
Treatment:
* H1 antihistamine (stop for less than 7 days) * Non-steroidal analgesics (stop for less than a week)* Central anti-hypertensive for 4 weeks- Corticosteroids: Nasal (stop for less than 7 days)Oral (if supported by more than 10 mg per day, stopping for less than a week)Intramuscular *Imipramine and other tricyclic treatment (stop for less than a week) *Ketotifen (stop for less than two weeks) *Leukotriene antagonists (stop for less than a week) * Nasal vasoconstrictors (one week)*
- Acute bacterial rhinosinusitis, systemic hypertension, myocardial infarction (<3 months), recent stroke (<3 months), known arterial aneurysm, epilepsy treatment, drug allergy
- Inability to measure a change in flow resistance and intra nasal (nasal obstruction complete)
- History of anaphylaxis to the allergen tested
- Nasal surgery 6-8 weeks before the study
- Subject exclusion period (determined by a previous study or in progress)
- Unable to give informed about the information (subject in an emergency situation, difficulties in understanding the subject)
- Inability to understand the maneuvers of nasal provocation test
- Subject in safeguarding justice, under guardianship
- Pregnancy and lactation
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Patients
A = Patients with allergic rhinitis sensitized to dust mites
|
TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year.
However, this test has not completely validated with a study including a significant number of patients.
That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites.
Our secondary objective is to compare the TPNC a faster TPN-called "minute" (60 minutes) and which allow a wider use.
If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites.
Altri nomi:
|
|
Control Subjects
B = control subjects with allergic rhinitis not sensitized to dust mites C = control subjects without allergic rhinitis
|
TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year.
However, this test has not completely validated with a study including a significant number of patients.
That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites.
Our secondary objective is to compare the TPNC a faster TPN-called "minute" (60 minutes) and which allow a wider use.
If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites.
Altri nomi:
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Jean-Jacques Braun, Hopitaux Universitaires de Strasbourg
- Direttore dello studio: Frédéric De Blay, Hopitaux Universitaires de Strasbourg
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 5103
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Nasal provocation test
-
Fundació Institut de Recerca de l'Hospital de la...CompletatoProgrammi per persone saneSpagna
-
Fisher and Paykel HealthcareCompletatoApnea ostruttiva del sonnoStati Uniti
-
Laboratoires Quinton International S.L.Non ancora reclutamentoRinite allergica | Congestione nasale | Raffreddore | Rinosinusite | Sintomo influenzaleSpagna
-
Medical University of South CarolinaCompletatoMalattia infettivaStati Uniti
-
Vyaire MedicalM.D. Anderson Cancer CenterCompletatoIpossiemiaStati Uniti
-
Airiver Medical, Inc.Attivo, non reclutante
-
Ottawa Hospital Research InstituteCompletatoIpertensione | Nefropatia diabetica | Diabete di tipo 2 | Apnea notturnaCanada
-
Chiesi Farmaceutici S.p.A.TerminatoSindrome da distress respiratorio neonataleItalia
-
Prime Gene Therapeutics Co., Ltd.Non ancora reclutamento
-
University Hospital, AntwerpCompletato